

## IN OTHER NEWS...

### TAXOTERE® RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER

**TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer**

BRIDGEWATER, NJ—MARCH 23, 2006 Sanofi-aventis announced today that following a priority review of the supplemental new drug application (sNDA), the U.S. Food and Drug Administration (FDA) has approved TAXOTERE® (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for the treatment of patients with advanced stomach (gastric) cancer, including cancer of the gastro esophageal (GE) junction, who have not received prior chemotherapy for advanced disease. This is the first FDA approval of an advanced stomach cancer treatment demonstrating a survival advantage in more than a decade, thereby offering physicians and their patients an important new option for treating this devastating disease. The additional new application is also currently under review by the Committee for Medicinal products for Human Use (CHMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

The FDA based its decision on results from the TAX 325 study, the largest international phase III clinical trial in previously untreated advanced stomach cancer, involving 445 patients. Patients treated with the TAXOTERE®-based chemotherapy regimen (TAXOTERE® plus cisplatin and 5-fluorouracil, TCF) experienced a significant 23 percent reduction in the risk of death compared to patients who received a current standard treatment of cisplatin and 5-fluorouracil (CF), (median follow-up: 23 months). The median overall survival was significantly longer with the TAXOTERE®-containing regimen (9.2 vs 8.6 months,  $p < 0.02$ ) with a hazard ratio of 1.29 (95% CI/ 1.19 -1.83).

Visit [www.oagpo.com](http://www.oagpo.com) (homepage: News and Events) to read this press release in its entirety.

### NEW PATIENT STARTER KIT AVAILABLE FOR XELODA:

Contact your local Roche Oncology Specialist for XELODA Patient Starter Kits, or contact OA at **888-732-7352**.

Materials to help patients initiating XELODA (capecitabine) therapy, including:

- > Patient product information
- > XTRA program patient brochure
- > "My XELODA Treatment Planner"
- > Pillbox
- > Emollient
- > "Cancer Chemotherapy and Hand-Foot Syndrome"
- > "Cancer Therapy and Oral Problems"



*Xeloda Patient Starter Kit*

### KYTRIL® \$25.00 MAIL-IN REBATE OFFER

To qualify for a rebate up to \$25, just complete a certificate (download at [www.oagpo.com](http://www.oagpo.com) on the homepage under News and Events), sign and mail with your pharmacy receipt.

Go to [www.oagpo.com](http://www.oagpo.com) to  
download certificate

Please submit the original pharmacy receipt along with the completed certificate to receive a rebate toward the cost of your prescription. Allow 6 to 8 weeks for receipt of your rebate check.

Mail to: Kytril® Rebate, C/O Triple i Customer Service Center, Box 2052, Morrisville, PA 19067-9781.

Offer not valid for prescriptions reimbursed or paid under Medicare, Medicaid or any similar federal or state healthcare program, including any state medical or pharmaceutical assistance programs. Void in the following states: Massachusetts, Texas and anywhere else prohibited by law. Offer also void where taxed or restricted. Amount of rebate not to exceed \$25.00 or patient out of pocket costs, whichever is less. This certificate may not be bought, transferred, copied or sold and must accompany this request. Limit 1 coupon per prescription and only in USA. Offer expires June 30, 2007. Roche Laboratories Inc. reserves the right to rescind, revoke or amend this offer without notice. By submitting this coupon for reimbursement, you agree to allow Roche to record your name and the information you have provided and to use this information in the future. All personal information will be kept strictly confidential and in accordance with state and federal law.